vs
Protalix BioTherapeutics, Inc.（PLX）与PROVIDENT FINANCIAL HOLDINGS INC（PROV）财务数据对比。点击上方公司名可切换其他公司
PROVIDENT FINANCIAL HOLDINGS INC的季度营收约是Protalix BioTherapeutics, Inc.的1.1倍（$9.8M vs $9.1M），PROVIDENT FINANCIAL HOLDINGS INC净利率更高（14.6% vs -60.3%，领先74.9%），PROVIDENT FINANCIAL HOLDINGS INC同比增速更快（2.5% vs -49.9%），Protalix BioTherapeutics, Inc.自由现金流更多（$1.6M vs $1.0M），过去两年PROVIDENT FINANCIAL HOLDINGS INC的营收复合增速更高（2.3% vs -6.7%）
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
普罗维登特金融控股公司是一家银行控股企业，通过旗下全资子公司普罗维登特储蓄银行开展业务，为美国加利福尼亚州当地社区提供各类存款、住房抵押贷款、消费贷款、小微企业融资等零售及商业金融服务。
PLX vs PROV — 直观对比
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $9.1M | $9.8M |
| 净利润 | $-5.5M | $1.4M |
| 毛利率 | 49.4% | — |
| 营业利润率 | -51.1% | 20.8% |
| 净利率 | -60.3% | 14.6% |
| 营收同比 | -49.9% | 2.5% |
| 净利润同比 | -184.8% | 64.7% |
| 每股收益（稀释后） | $-0.06 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $9.1M | $9.8M | ||
| Q3 25 | $17.9M | $9.7M | ||
| Q2 25 | $15.7M | $9.8M | ||
| Q1 25 | $10.1M | $10.1M | ||
| Q4 24 | $18.2M | $9.6M | ||
| Q3 24 | $18.0M | $9.5M | ||
| Q2 24 | $13.5M | $9.9M | ||
| Q1 24 | — | $9.4M |
| Q4 25 | $-5.5M | $1.4M | ||
| Q3 25 | $2.4M | $1.7M | ||
| Q2 25 | $164.0K | $1.6M | ||
| Q1 25 | $-3.6M | $1.9M | ||
| Q4 24 | $6.5M | $872.0K | ||
| Q3 24 | $3.2M | $1.9M | ||
| Q2 24 | $-2.2M | $2.0M | ||
| Q1 24 | — | $1.5M |
| Q4 25 | 49.4% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 62.5% | — | ||
| Q1 25 | 19.1% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 53.4% | — | ||
| Q2 24 | 29.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | -51.1% | 20.8% | ||
| Q3 25 | 11.9% | 28.1% | ||
| Q2 25 | 7.5% | 23.6% | ||
| Q1 25 | -41.0% | 26.2% | ||
| Q4 24 | 39.6% | 12.7% | ||
| Q3 24 | 22.2% | 28.3% | ||
| Q2 24 | -18.0% | 27.8% | ||
| Q1 24 | — | 22.5% |
| Q4 25 | -60.3% | 14.6% | ||
| Q3 25 | 13.2% | 17.3% | ||
| Q2 25 | 1.0% | 16.7% | ||
| Q1 25 | -35.8% | 18.4% | ||
| Q4 24 | 35.6% | 9.1% | ||
| Q3 24 | 18.0% | 20.0% | ||
| Q2 24 | -16.4% | 19.7% | ||
| Q1 24 | — | 15.9% |
| Q4 25 | $-0.06 | $0.22 | ||
| Q3 25 | $0.03 | $0.25 | ||
| Q2 25 | $0.00 | $0.24 | ||
| Q1 25 | $-0.05 | $0.28 | ||
| Q4 24 | $0.10 | $0.13 | ||
| Q3 24 | $0.03 | $0.28 | ||
| Q2 24 | $-0.03 | $0.28 | ||
| Q1 24 | — | $0.22 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $14.7M | $54.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $48.2M | $127.5M |
| 总资产 | $82.3M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $14.7M | $54.4M | ||
| Q3 25 | $13.6M | $49.4M | ||
| Q2 25 | $17.9M | $53.1M | ||
| Q1 25 | $19.5M | $50.9M | ||
| Q4 24 | $19.8M | $45.5M | ||
| Q3 24 | $27.4M | $48.2M | ||
| Q2 24 | $23.4M | $51.4M | ||
| Q1 24 | — | $51.7M |
| Q4 25 | $48.2M | $127.5M | ||
| Q3 25 | $52.9M | $128.4M | ||
| Q2 25 | $49.9M | $128.5M | ||
| Q1 25 | $45.2M | $128.9M | ||
| Q4 24 | $43.2M | $128.6M | ||
| Q3 24 | $32.4M | $129.6M | ||
| Q2 24 | $28.6M | $129.9M | ||
| Q1 24 | — | $129.5M |
| Q4 25 | $82.3M | $1.2B | ||
| Q3 25 | $82.3M | $1.2B | ||
| Q2 25 | $78.5M | $1.2B | ||
| Q1 25 | $73.9M | $1.3B | ||
| Q4 24 | $73.4M | $1.3B | ||
| Q3 24 | $61.6M | $1.3B | ||
| Q2 24 | $91.5M | $1.3B | ||
| Q1 24 | — | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.0M | $1.2M |
| 自由现金流经营现金流 - 资本支出 | $1.6M | $1.0M |
| 自由现金流率自由现金流/营收 | 17.8% | 10.5% |
| 资本支出强度资本支出/营收 | 4.4% | 1.9% |
| 现金转化率经营现金流/净利润 | — | 0.85× |
| 过去12个月自由现金流最近4个季度 | $-13.6M | $14.9M |
8季度趋势，按日历期对齐
| Q4 25 | $2.0M | $1.2M | ||
| Q3 25 | $-3.7M | $2.5M | ||
| Q2 25 | $-5.2M | $8.7M | ||
| Q1 25 | $-5.1M | $3.3M | ||
| Q4 24 | $4.0M | $324.0K | ||
| Q3 24 | $4.1M | $2.6M | ||
| Q2 24 | $-3.6M | $5.7M | ||
| Q1 24 | — | $3.0M |
| Q4 25 | $1.6M | $1.0M | ||
| Q3 25 | $-4.2M | $2.5M | ||
| Q2 25 | $-5.7M | $8.2M | ||
| Q1 25 | $-5.4M | $3.3M | ||
| Q4 24 | $3.6M | $307.0K | ||
| Q3 24 | $4.0M | $2.4M | ||
| Q2 24 | $-3.8M | $4.1M | ||
| Q1 24 | — | $2.6M |
| Q4 25 | 17.8% | 10.5% | ||
| Q3 25 | -23.7% | 25.2% | ||
| Q2 25 | -36.2% | 83.5% | ||
| Q1 25 | -53.0% | 32.5% | ||
| Q4 24 | 19.6% | 3.2% | ||
| Q3 24 | 22.4% | 25.1% | ||
| Q2 24 | -28.1% | 41.3% | ||
| Q1 24 | — | 27.5% |
| Q4 25 | 4.4% | 1.9% | ||
| Q3 25 | 2.8% | 0.5% | ||
| Q2 25 | 2.8% | 5.4% | ||
| Q1 25 | 3.0% | 0.3% | ||
| Q4 24 | 2.3% | 0.2% | ||
| Q3 24 | 0.5% | 1.8% | ||
| Q2 24 | 1.3% | 16.0% | ||
| Q1 24 | — | 4.2% |
| Q4 25 | — | 0.85× | ||
| Q3 25 | -1.58× | 1.48× | ||
| Q2 25 | -31.91× | 5.34× | ||
| Q1 25 | — | 1.79× | ||
| Q4 24 | 0.61× | 0.37× | ||
| Q3 24 | 1.27× | 1.35× | ||
| Q2 24 | — | 2.91× | ||
| Q1 24 | — | 2.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
PROV
暂无分部数据
